These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators. Maron BJ; Casey SA; Olivotto I; Sherrid MV; Semsarian C; Autore C; Ahmed A; Boriani G; Francia P; Winters SL; Giudici M; Koulova A; Garberich R; Rowin EJ; Sears SF; Maron MS; Spirito P Circ Arrhythm Electrophysiol; 2018 Apr; 11(4):e005820. PubMed ID: 29625970 [TBL] [Abstract][Full Text] [Related]
31. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. Maron BJ; Spirito P; Shen WK; Haas TS; Formisano F; Link MS; Epstein AE; Almquist AK; Daubert JP; Lawrenz T; Boriani G; Estes NA; Favale S; Piccininno M; Winters SL; Santini M; Betocchi S; Arribas F; Sherrid MV; Buja G; Semsarian C; Bruzzi P JAMA; 2007 Jul; 298(4):405-12. PubMed ID: 17652294 [TBL] [Abstract][Full Text] [Related]
32. Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. Maron BJ Circ J; 2010 Nov; 74(11):2271-82. PubMed ID: 20962423 [TBL] [Abstract][Full Text] [Related]
33. Hypertrophic cardiomyopathy: a review of etiology and treatment. Jurynec J J Cardiovasc Nurs; 2007; 22(1):65-73; quiz 74-5. PubMed ID: 17224700 [TBL] [Abstract][Full Text] [Related]
34. Unmet needs in the treatment of hypertrophic cardiomyopathy. Hutt E; Nissen SE; Desai MY Future Cardiol; 2021 Oct; 17(7):1261-1267. PubMed ID: 33960215 [TBL] [Abstract][Full Text] [Related]
35. Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator. Maron BJ; Rowin EJ; Maron MS Heart Rhythm; 2021 Jun; 18(6):1012-1023. PubMed ID: 33508516 [TBL] [Abstract][Full Text] [Related]
36. Abnormalities in sodium current and calcium homoeostasis as drivers of arrhythmogenesis in hypertrophic cardiomyopathy. Coppini R; Santini L; Olivotto I; Ackerman MJ; Cerbai E Cardiovasc Res; 2020 Jul; 116(9):1585-1599. PubMed ID: 32365196 [TBL] [Abstract][Full Text] [Related]
37. Advances in the Management of Hypertrophic Cardiomyopathy Leading to Low Disease-Related Mortality in 2023. Maron BJ; Rowin EJ; Maron MS Am J Cardiol; 2024 Feb; 212S():S77-S82. PubMed ID: 38368039 [TBL] [Abstract][Full Text] [Related]
38. Hypertrophic cardiomyopathy. Subasic K Nurs Clin North Am; 2013 Dec; 48(4):571-84. PubMed ID: 24295188 [TBL] [Abstract][Full Text] [Related]
39. Implantable cardioverter defibrillator therapy and sudden death risk stratification in hypertrophic cardiomyopathy patients with midventricular obstruction: A single-center experience. Maeda R; Minami Y; Haruki S; Kanbayashi K; Itani R; Suzuki A; Ejima K; Shiga T; Shoda M; Hagiwara N Int J Cardiol; 2016 Jul; 214():419-22. PubMed ID: 27088403 [TBL] [Abstract][Full Text] [Related]
40. [Hypertrophic cardiomyopathy]. van Driel B; Asselbergs FW; de Boer RA; van Rossum AC; van Tintelen JP; van der Velden J; Michels M Ned Tijdschr Geneeskd; 2019 Feb; 163():. PubMed ID: 30730688 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]